Skip to main content
Fig. 1 | Clinical Proteomics

Fig. 1

From: Use of MS-GUIDE for identification of protein biomarkers for risk stratification of patients with prostate cancer

Fig. 1

Diagnostic and prognostic biomarker assay development using MS-GUIDE. In a pre-qualification step, PRM-MS is used to screen a high number of potential biomarkers in a multiplexed fashion in samples from a small cohort. For identified candidates, a clinical-level sandwich ELISA is established. ELISAs are highly specific, quantitatively robust, and enable the measurement of hundreds of samples at a time and can therefore be used to validate biomarkers in large cohorts

Back to article page

Clinical Proteomics

ISSN: 1559-0275